The U.S. Food and Drug Administration (FDA) approved the first blood test to detect Alzheimer's disease in what federal officials called an "important step" toward diagnosing and treating the ...

A Malvern company has received FDA clearance for a first-of-its-kind blood test to help diagnose Alzheimer's disease. Health experts say the test could revolutionize the diagnosis and care of ...

The FDA has cleared the first blood test to diagnose Alzheimer's which works by measuring the amount of pTau 217 and beta-amyloid 1-42 in plasma.

The U.S. Food and Drug Administration has cleared marketing for a new blood test to diagnose Alzheimer's disease in people who are already exhibiting symptoms.This new test is the first blood test ...

The U.S. Food and Drug Administration (FDA) has granted approval for a first-of-its-kind blood test to help diagnose Alzheimer’s disease, which could help people begin treatment in the early ...

The FDA's sign-off on marketing for Fujirebio's test comes years after other blood tests for Alzheimer's have already begun sales, without this kind of approval from the agency.

The first-ever blood test to detect Alzheimer’s disease has been cleared by the U.S. Food and Drug Administration (FDA). In a Friday press release, the agency announced its approval of the first ...

The presence of amyloid plaques, sticky substances in the brain, is a hallmark of Alzheimer’s disease — though the role it plays is a matter of debate among neurologists. The FDA has approved ...

It's paving the way for new and more exciting treatments to come."The clinic's first patient to use the drug was Karen Heathcock of Lincoln."This is the best thing that's happened to me," she said ...

A drug originally developed to treat a rare neurological disease that weakens nerve cells in the brain and spinal cord may also hold promise for combating Alzheimer's, according to new research ...

The U.S. Food and Drug Administration on Friday approved a new blood test for the early detection of Alzheimer's disease in patients beginning to show cognitive decline.